Navigation Links
Circulating Tumor Cells Reveal Insights Into Lung Cancers
Date:7/2/2008

Technology could one day help tailor treatments to individual patients, study says

WEDNESDAY, July 2 (HealthDay News) -- A new technique for finding and analyzing stray cancer cells in the blood of lung cancer patients may make it possible for doctors to one day not only determine the genetic "signature" of particular tumors but to monitor changes in those cells and adjust treatments accordingly.

"I think this is key to personalized medicine," said Dr. Daniel Haber, senior author of a paper detailing the technology, to be published in the July 24 issue of the New England Journal of Medicine but released early online Wednesday. "As we get to targeted therapies in increasing numbers, and increasing understanding about the genetics that guide targeted therapies, we need a way to know what we're treating."

The "CTC chip" technology described in the new paper may also one day aid in the detection of cancers that are likely to spread. "This is an early warning sign we could use for earlier detection," said Haber, who is director of the Massachusetts General Hospital Cancer Center in Boston.

A previous study published in Nature used the CTC (Circulating Tumor Cells) chip technology to look at CTCs in lung, pancreatic, prostate, breast and colon cancers. The CTC chip successfully found such cells in 99 percent of the samples.

"We're very interested in the biology of these cells because no one has really been able to study metastasis [spread of cancer to other parts of the body] in action," Haber said. "These are the cells that cause metastases and the lethality of cancer. Now that we can identify and purify them in decent numbers, we can study and hopefully identify some of their vulnerabilities. It opens up a whole field of human metastasis and human therapies."

The CTC chip is a silicon chip about the size of a business card that has 80,000 "columns" coded with an antibody that acts like a "glue" to capture tumor cells "that have no business being in the blood," Haber explained.

Haber and his colleagues analyzed blood samples from 27 patients with non-small cell lung cancer, 23 who had EGFR gene mutations and four who did not. CTCs were identified in all samples and in genetic analyses from mutations 92 percent of the time.

Mutations in EGFR, a protein, can help predict whether these tumors will respond to a family of drugs called tyrosine kinase inhibitors.

"Even in the three to four months that we followed patients, the genetic make-up of the tumors changed. Resistant mutations appear and other mutations appear, obviously because we're doing things [with drug therapy] to the cancer," Haber said. "But the way we practice oncology we don't typically test for that. We do one biopsy which takes a tiny, tiny amount and assume that for the rest of the course, the tumor is the same."

"It's important to know in real time what you're treating," he continued. "We need to be able to follow the patient without needing to re-biopsy the tumor every time."

The technology is in its infancy, however. "This is still in a very, very early stage where it takes a long time to handle every sample, to flow the blood through the chip," Haber said. "This is a proof of principle that we can do this. We need a much more automated system for larger clinical trials."

Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, said that "you have to have some circulating cells to do this test, but it's very exciting because they're getting a genetic fingerprint of a tumor which will tell an oncologist what therapy the tumor might respond to or not respond to.

"It's expensive, but it may well be that if we can identify patients who can have a personalized regimen that works, we will be saving the cost of treating all those patients with regimens that don't work," he added.

Two other studies looking at lung cancer are published in the July issue of the Journal of Thoracic Oncology.

One, a review of existing studies, concluded that analyzing so-called volatile organic compounds in the breath of lung cancer patients may hold promise as a tool to detect cancer earlier. The technique deserves further attention, said researchers from the Cleveland Clinic.

For the second study, researchers at the University of Alabama at Birmingham found certain socioeconomic factors that may contribute to a higher death rate among blacks with non-small cell lung cancer. These included a higher smoking rate among blacks patients than white patients; a greater delay to the start of treatment among blacks; and less willingness to undergo chemotherapy among blacks than their white counterparts.

More information

Visit the U.S. National Cancer Institute for more on lung cancer.



SOURCES: Daniel A. Haber, M.D., Ph.D., director, Massachusetts General Hospital Cancer Center, Boston; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; July 24, 2008, New England Journal of Medicine; Dec. 20, 2007, Nature


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Circulating fats kill transplanted pancreas cells, study shows
2. FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients
3. High circulating D-dimers are associated with presence of ascites
4. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
5. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
6. Study details regulation of vital tumor suppressor gene p53
7. Human C-reactive protein regulates myeloma tumor cell growth and survival
8. Customized virus kills brain tumor stem cells that drive lethal cancer
9. Study suggests brain tumors need treatment with multiple targeted drugs
10. Bright tumors, dim prospects
11. National Brain Tumor Foundation Unites with BrainLAB in Support of Patient Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of ... Frederick, MD. Judy says, “I am passionate about sharing Reiki as a holistic, ... difficult and challenging time.” , A Certified Medical Reiki™ Master trained by Raven ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a ... will interrelate. “End Time GPS” is the creation of published author, Wesley Gerboth, ... working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares the ...
(Date:3/24/2017)... ... , ... “The Communion of Saints: A Pastor’s Potpourri of ... across the United States. “The Communion of Saints” is the creation of ... congregations in seven states throughout his long career of devotion to the church. ...
(Date:3/23/2017)... WA (PRWEB) , ... March 23, 2017 , ... In ... and now estimates that there could be four million Zika-related cases in the Americas ... date with numbers of US cases reported per year skyrocketing to an estimated 329,000. ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Oregon and PUNE, India , March 24, 2017 /PRNewswire/ ... 2015, and is estimated to reach $2,614 million by 2022, Globally, registering a CAGR ... to generate the highest revenue, and is projected to dominate the market during the ... ... Allied Market Research Logo ...
(Date:3/24/2017)... , March 24, 2017  Zymo Research ... and Hamilton Robotics, Inc., who designs, manufactures ... ongoing collaboration that teams Zymo Research,s DNA ... and DNA extraction products with Hamilton,s high-throughput ... optimized methods for microbiomics and RNA isolation ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental Implants ... ... for Dental Implants in US$ Million. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through 2022. ...
Breaking Medicine Technology: